5Ranson M.Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer[J].J Natl Cancer Inst,2000,92(13):1074-1080.
二级参考文献8
1[2]Fossella FV, DeVore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol,2000,18(12)∶2354-2362.
2[3]Ellis PA, Smith IE, Hardy JK, et al. Symptom relief with MVP chemotherapy in advanced non-small-cell lung cancer. Br J Cancer,1995,71(2)∶366-370.
3[4]Buccheri G, Vola F, Ferrigno D. Aspects of quality of life of patients with lung cancer: a three observer evaluation in study. Int J Oncol,1993,2(2)∶537-544.
4[5]Ferrigno D, Buccheri G. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer,2000,29(2)∶91-104.
5[6]Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol,2000,18(10)∶2095-2103.
6[7]Akerley W 3rd. Paclitaxel in advanced non-small-cell lung cancer: an alternative high-dose weekly schedule. Chest,2000,117(4 Suppl 1)∶152S-155S.
7[8]Belani CP. Interim analysis of a phase Ⅱ study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer. Semin Oncol,2001,28(4 Suppl 14)∶14-16.
8[9]Stathopoulos GP, Rigatos S, Malamos NA. Paclitaxel combined with cisplatin as second-line treatment in patients with advanced non-small-cell lung cancers refractory to cisplatin. Oncol Rep,1999,6(4)∶797-800.
3Schiller JH, Harington D, Belanie CP, et al. Compmison of four chemotherapy regimens for advanced non small call lung cancer [J]. New Eng J Med , 2002,346 (2) :92-98.
